| Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer (NCT05859477) | Kidney Cancer Research Bureau | 2022-06-05 |
| Fruquintinib Combined With Toripalimab and SOX Regimen in the First-line Treatment of Advanced Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (NCT05024812) | The First Affiliated Hospital of Zhengzhou University | 2022-06-01 |
| Clinical Outcome of Palliative Surgery After Translational Therapy for Metastatic Gastric Cancer Versus Maintenance Chemotherapy for Metastatic Gastric Cancer (NCT05230771) | Fujian Medical University | 2022-04-01 |
| Study Evaluating Neurotoxicity in Patients With Metastatic Gastro Intestinal Cancer Taking Phycocare® or Placebo During Oxaliplatin Based Chemotherapy (NCT05025826) | Nantes University Hospital | 2022-04-01 |
| Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer (NCT05183126) | University of Michigan Rogel Cancer Center | 2022-03-28 |
| A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors (NCT05143970) | Institut Paoli-Calmettes | 2022-01-21 |
| Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST) (NCT04739202) | Hospices Civils de Lyon | 2021-03-19 |
| Deciphering the Molecular Traits of Non-canonical Responders to Advance Personalized Therapy in Gastric Cancer (NCT06877910) | Regina Elena Cancer Institute | 2021-01-10 |
| Conversion Effects of PD-1 Antibody Camrelizumab Combined With Nab-POF Regimen Chemotherpy in Patients With Initially Unresectable Locally Advanced or Limited Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma：FDZL-GC001 Trial (NCT04510064) | Fudan University | 2021-01-06 |
| Triplet Combination of Cytotoxics as First-line Treatment for Metastatic Gastric Cancer (NCT04358354) | Sixth Affiliated Hospital, Sun Yat-sen University | 2020-10-22 |
| Improving the Approach to and Management of the Older Patient With Metastatic Gastric Cancer (NCT04618809) | Fox Chase Cancer Center | 2020-09-22 |
| Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction (NCT04263870) | Sichuan University | 2020-03-01 |
| WaKING: Wnt and checKpoint INhibition in Gastric Cancer (NCT04166721) | Royal Marsden NHS Foundation Trust | 2020-02-11 |
| TEW-7197 with Paclitaxel for the Treatment of Metastatic Gastric Cancer (NCT03698825) | MedPacto, Inc. | 2018-08-15 |
| Resistance to Immunotherapy in Gastric Cancer (NCT03614013) | Pontificia Universidad Catolica de Chile | 2018-07-04 |
| GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study (NCT03751761) | Asan Medical Center | 2018-06-11 |
| Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma (NCT03409848) | AIO-Studien-gGmbH | 2018-03-01 |
| Clinical Study to Compare the Pharmacokinetics and Safety of Trastuzumab for Injection With Herceptin® in Healthy Male Volunteers (NCT05765357) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2017-07-16 |
| The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer (NCT03154983) | Zhou Fuxiang | 2017-05-20 |
| Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects (NCT02310464) | OBI Pharma, Inc | 2015-12-22 |
| An Open Label, Prospective, Multicentre, Non-interventional Study of Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer (NCT02668380) | Peking Union Medical College Hospital | 2015-09-01 |
| Home Parenteral Nutrition for Malnourished Unresectable Stage IV Gastric Cancer (NCT03121807) | Kaohsiung Medical University Chung-Ho Memorial Hospital | 2014-09-01 |
| Genotype Guided Chemotherapy in Gastric Cancer Patients (NCT02204306) | Central South University | 2014-04-01 |
| Modified Folinic Acid-Fluorouracil-Oxaliplatin Regimen + Capecitabine for Elderly With Metastatic Gastric Cancer (NCT02002195) | International Group of Endovascular Oncology | 2013-11-01 |
| The Association Between Alpha 1 Acid Glycoprotein Level and Outcome Metastatic Cancer Treated With Docetaxel (NCT01814150) | Gottfried Maya | 2013-04-01 |
| Low-Tox Vs Eox In Patients With Locally Advanced Unresectable Or Metastatic Gastric Cancer (NCT02076594) | Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente | 2013-01-01 |
| Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer (NCT01359397) | The Netherlands Cancer Institute | 2011-03-01 |
| Histone Deacetylases - Gastric Cancer (HDAC-GaCa-2008) (NCT01528501) | Technical University of Munich | 2009-06-01 |
| Low-dose RAD001(Everolimus) Plus Cisplatin-HDFL Chemotherapy for the First-line Treatment of Advanced Gastric Cancer (NCT00632268) | National Taiwan University Hospital | 2008-02-01 |
| Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer (NCT00253370) | National Cancer Institute (NCI) | 2005-10-01 |
| International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer (NCT02065765) | Eli Lilly and Company | |